利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.012 秒)

    Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis
    1.
    发明授权
    Pharmaceutical composition with enhanced efficacy for inhibiting angiogenesis 有权
    具有增强抑制血管发生功效的药物组合物

    公开(公告)号：US09371286B2

    公开(公告)日：2016-06-21

    申请号：US14232598

    申请日：2011-05-23

    申请人： Ho Jeong Kwon ,  Gyoon Hee Han ,  Hye Jin Jung ,  Jeong Jea Seo

    发明人： Ho Jeong Kwon ,  Gyoon Hee Han ,  Hye Jin Jung ,  Jeong Jea Seo

    IPC分类号： C07D215/38 ,  C07C311/21 ,  C07C311/20

    CPC分类号： C07D215/38 ,  C07C311/20 ,  C07C311/21 ,  C07C2601/14

    摘要： The present invention relates to a pharmaceutical composition for inhibiting angiogenesis and a novel sulfonyl amide derivative compound which can be useful for the prevention or treatment of angiogenesis-related diseases or disorders. Since the compound used as an active ingredient in the pharmaceutical composition of the invention is specifically bound to UQCRB and inhibits biological functions thereof, apoptosis is not induced and angiogenic responses are inhibited. Therefore, the compound used as an active ingredient in the pharmaceutical composition of the invention can be useful as an effective and safe angiogenesis inhibitory agent.

    摘要翻译： 本发明涉及一种抑制血管发生的药物组合物和一种可用于预防或治疗血管生成相关疾病或病症的新型磺酰基酰胺衍生物化合物。 由于用作本发明的药物组合物中的活性成分的化合物与UQCRB特异性结合并抑制其生物学功能，因此不诱导细胞凋亡并且抑制血管生成反应。 因此，本发明的药物组合物中作为活性成分使用的化合物可用作有效且安全的血管生成抑制剂。

    Pharmaceutical compositions for inhibiting angiogenesis
    3.
    发明授权
    Pharmaceutical compositions for inhibiting angiogenesis 有权
    用于抑制血管生成的药物组合物

    公开(公告)号：US08450502B2

    公开(公告)日：2013-05-28

    申请号：US12865356

    申请日：2009-01-30

    申请人： Ho Jeong Kwon ,  Hye Jin Jung

    发明人： Ho Jeong Kwon ,  Hye Jin Jung

    IPC分类号： C07D333/50 ,  A61P35/00

    CPC分类号： A61K31/381

    摘要： Provided is a pharmaceutical composition for inhibiting angiogenesis, comprising a therapeutically effective amount of a compound represented by Formula 1: (I) wherein R1 through R13 and X are as defined in the specification. Compounds used as an active ingredient in the pharmaceutical composition of the present invention bind to QP-C to provide effective prevention of angiogenesis and can be effectively used for prevention and/or treatment of angiogenesis-related diseases or disorders. Further, the active compounds of the present invention inhibit biological functions of QP-C, which consequently leads to inhibition of angiogenic responses without the risk of cellular apoptosis, thus significantly improving safety of the drug.

    摘要翻译： 本发明提供一种抑制血管生成的药物组合物，其含有治疗有效量的式1表示的化合物：（Ⅰ）其中R1至R13和X如说明书中所定义。 在本发明的药物组合物中用作活性成分的化合物与QP-C结合以提供有效的血管发生预防，并可有效地用于预防和/或治疗血管发生相关疾病或病症。 此外，本发明的活性化合物抑制QP-C的生物学功能，其结果导致血管生成反应的抑制而没有细胞凋亡的风险，因此显着提高了药物的安全性。

    Stilbene derivatives for ADP-ribosyl cyclase inhibitors
    5.
    发明授权
    Stilbene derivatives for ADP-ribosyl cyclase inhibitors 有权
    ADP-核糖基环化酶抑制剂的二苯乙烯衍生物

    公开(公告)号：US08314082B2

    公开(公告)日：2012-11-20

    申请号：US13149166

    申请日：2011-05-31

    申请人： Uh-Hyun Kim ,  Ho-Jeong Kwon ,  Mie-Jae Im ,  Seon-Young Kim ,  Kwang-Hyun Park ,  So-Young Rah ,  Tae-Sik Nam ,  Byung-Ju Kim ,  Gul Rukhsana

    发明人： Uh-Hyun Kim ,  Ho-Jeong Kwon ,  Mie-Jae Im ,  Seon-Young Kim ,  Kwang-Hyun Park ,  So-Young Rah ,  Tae-Sik Nam ,  Byung-Ju Kim ,  Gul Rukhsana

    IPC分类号： A61K31/05

    CPC分类号： C07C245/08 ,  C07C39/215

    摘要： The present disclosure relates to bisphenyl compounds that are useful for inhibiting the ADP-ribosyl cyclase (ADPR-cyclase). More particularly, the disclosed compounds can be used for treatment and prevention of hypertension, hypertensive cardiac hypertrophy, diabetes, and diabetic nephropathy, in which pathogenesis ADPR-cyclase is involved. The compounds and compositions of the invention can be used for treatment and prevention of cardiovascular disease and related disease states, particularly, hypertension or diabetes related disorders, such as, hypertensive cardiac hypertrophy, diabetic nephropathy, and the like.

    摘要翻译： 本公开涉及可用于抑制ADP-核糖基环化酶（ADPR-环化酶）的双苯基化合物。 更具体地，所公开的化合物可用于治疗和预防涉及发病机制ADPR-环化酶的高血压，高血压心脏肥大，糖尿病和糖尿病性肾病。 本发明的化合物和组合物可用于治疗和预防心血管疾病和相关疾病状态，特别是高血压或糖尿病相关疾病，例如高血压心脏肥大，糖尿病性肾病等。

    Protein inhibiting aggregation of beta amyloid peptide
    6.
    发明授权
    Protein inhibiting aggregation of beta amyloid peptide 有权
    蛋白抑制β淀粉样蛋白聚集

    公开(公告)号：US07112569B2

    公开(公告)日：2006-09-26

    申请号：US10884729

    申请日：2004-07-02

    申请人： Sangmee Ahn Jo ,  Inho Jo ,  Ho Jeong Kwon ,  Chang Jin Kim ,  Jeong Eun Park

    发明人： Sangmee Ahn Jo ,  Inho Jo ,  Ho Jeong Kwon ,  Chang Jin Kim ,  Jeong Eun Park

    IPC分类号： A61K38/00

    CPC分类号： C07H21/04 ,  A61K38/00 ,  C07K14/4711

    摘要： The present invention relates to a novel protein inhibiting β amyloid aggregation and a strain producing the protein, more precisely, to a novel protein inhibiting β amyloid aggregation, a gene coding the protein, a Streptomyces sp. strain producing the protein and a therapeutic agent for neurodegenerative disorders containing the protein as an effective ingredient. The therapeutic agent of the present invention containing the protein inhibiting β amyloid aggregation as an effective ingredient can be effectively used for the prevention and the treatment of neurodegenerative disorders like Alzheimer's disease.

    摘要翻译： 本发明涉及抑制β-淀粉样蛋白的新型蛋白质聚集和产生蛋白质的菌株，更确切地说，涉及一种抑制β-淀粉样蛋白聚集的新蛋白质，一种编码该蛋白质的基因，一种链霉菌属（Streptomyces sp。）。 产生蛋白质的菌株和含有蛋白质作为有效成分的神经变性疾病的治疗剂。 含有蛋白质抑制β淀粉样蛋白聚集作为有效成分的本发明治疗剂可有效地用于预防和治疗神经变性疾病如阿尔茨海默氏病。

    Wondonin A and process for preparing the same
    7.
    发明授权
    Wondonin A and process for preparing the same 有权
    Wondonin A和准备相同的过程

    公开(公告)号：US06383521B1

    公开(公告)日：2002-05-07

    申请号：US09839393

    申请日：2001-04-20

    申请人： Jong-Heon Shin ,  Ki-Woong Cho ,  Young-Wan Seo ,  Jung-Rae Rho ,  Hyi-Seung Lee ,  Ho-Jeong Kwon

    发明人： Jong-Heon Shin ,  Ki-Woong Cho ,  Young-Wan Seo ,  Jung-Rae Rho ,  Hyi-Seung Lee ,  Ho-Jeong Kwon

    IPC分类号： C07D30700

    CPC分类号： C07D405/06

    摘要： The present invention provides Wondonin A of general formula (I), which is extracted from a two-sponge association of phylum Porifera (sponge) and has antiangiogenic activity, and a process for preparing the same. Wondonin A has no cytotoxicity, but has an inhibitory activity against angiogenesis which is one of the crucial mechanisms of cancer cell metastasis, thus, it can be applied not only as an anticancer drug but also as a therapeutic agent of angiogenesis-associated diseases such as cardiac ischemia, rheumatoid arthritis, and diabetes mellitus.

    摘要翻译： 本发明提供了通式（I）的Wondonin A，其由Porifera（海绵）的双海绵结合物提取并具有抗血管生成活性及其制备方法。 Wondonin A没有细胞毒性，但对血管生成具有抑制作用，这是癌细胞转移的关键机制之一，因此不仅可以用作抗癌药物，还可以用作血管生成相关疾病的治疗剂，例如 心脏缺血，类风湿性关节炎和糖尿病。

    PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AUTOPHAGY-RELATED DISEASES, ANGIOGENIC DISEASES OR MELANIN-RELATED DISEASES
    8.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AUTOPHAGY-RELATED DISEASES, ANGIOGENIC DISEASES OR MELANIN-RELATED DISEASES 有权
    用于预防或治疗自身相关疾病，抗原性疾病或梅毒素相关疾病的药物组合物

    公开(公告)号：US20130251654A1

    公开(公告)日：2013-09-26

    申请号：US13990301

    申请日：2011-09-06

    申请人： Ho Jeong Kwon ,  Yoon Sun Cho

    发明人： Ho Jeong Kwon ,  Yoon Sun Cho

    IPC分类号： C07C211/42 ,  A61Q19/02 ,  A61K8/41

    CPC分类号： C07C211/42 ,  A61K8/41 ,  A61K31/135 ,  A61Q19/02

    摘要： The present invention relates to a pharmaceutical composition for preventing or treating autophagy-related diseases, angiogenic diseases or hypermelanosis, comprising: (a) a pharmaceutically effective amount of an indatraline derivative or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The composition of the present invention effectively induces autophagy of cells, and thus is very effective for preventing or treating autophagy-related diseases. In addition, the composition of the present invention inhibits angiogenesis through the mechanism of inhibiting angiogenesis, invasion and metastasis and inhibits melanogenesis, and thus can also be effective for preventing or treating angiogenic diseases or melanin-related diseases.

    摘要翻译： 本发明涉及一种用于预防或治疗自噬相关疾病，血管生成疾病或高致命性黑素沉着症的药物组合物，其包含：（a）药物有效量的靛蓝烷衍生物或其药学上可接受的盐; 和药学上可接受的载体。 本发明的组合物有效地诱导细胞自噬，因此对于预防或治疗自噬相关疾病非常有效。 此外，本发明的组合物通过抑制血管发生，侵袭和转移的机制抑制血管生成并抑制黑素生成，因此也可有效预防或治疗血管生成疾病或黑色素相关疾病。

    PHARMACEUTICAL COMPOSITION WITH ENHANCED EFFICACY FOR INHIBITING ANGIOGENESIS
    10.
    发明申请
    PHARMACEUTICAL COMPOSITION WITH ENHANCED EFFICACY FOR INHIBITING ANGIOGENESIS 有权
    具有增强抑制血管生成作用的药物组合物

    公开(公告)号：US20140315947A1

    公开(公告)日：2014-10-23

    申请号：US14232598

    申请日：2011-05-23

    申请人： Ho Jeong Kwon ,  Gyoon Hee Han ,  Hye Jin Jung ,  Jeong Jea Seo

    发明人： Ho Jeong Kwon ,  Gyoon Hee Han ,  Hye Jin Jung ,  Jeong Jea Seo

    IPC分类号： C07D215/38 ,  C07C311/21

    CPC分类号： C07D215/38 ,  C07C311/20 ,  C07C311/21 ,  C07C2601/14

    摘要： The present invention relates to a pharmaceutical composition for inhibiting angiogenesis and a novel sulfonyl amide derivative compound which can be useful for the prevention or treatment of angiogenesis-related diseases or disorders. Since the compound used as an active ingredient in the pharmaceutical composition of the invention is specifically bound to UQCRB and inhibits biological functions thereof, apoptosis is not induced and angiogenic responses are inhibited. Therefore, the compound used as an active ingredient in the pharmaceutical composition of the invention can be useful as an effective and safe angiogenesis inhibitory agent.

    摘要翻译： 本发明涉及一种抑制血管发生的药物组合物和一种可用于预防或治疗血管生成相关疾病或病症的新型磺酰基酰胺衍生物化合物。 由于用作本发明的药物组合物中的活性成分的化合物与UQCRB特异性结合并抑制其生物学功能，因此不诱导细胞凋亡并且抑制血管生成反应。 因此，本发明的药物组合物中作为活性成分使用的化合物可用作有效且安全的血管生成抑制剂。